Skip to main content

Table 3 Levels of ceramides quantified in lean and obese groups (A and B) and that in after stratifying obese into obese-NDM and obese-DM groups (C and D)

From: Insulin resistance induced by de novo pathway–generated C16-ceramide is associated with type 2 diabetes in an obese population

Ceramides Lean (A) Obese (B) P Value (A Vs B) Obese-NDM (C) Obese-DM (D) P Value (C Vs D)
N = 20  N = 98  N = 66  N = 32
Mean ± SD (pg/mg) Mean ± SD (pg/mg) Mean ± SD (pg/mg) Mean ± SD (pg/mg)
C16-ceramide 25.09 ± 9.67 38.56 ± 25.58 0.023* 34.59 ± 12.08 46.75 ± 39.97 0.027*
C16-dihydro-ceramide 0.34 ± 0.12 0.53 ± 0.25 < 0.005* 0.51 ± 0.20 0.58 ± 0.33 0.198
C18-ceramide 1.44 ± 0.45 1.63 ± 0.48 0.114 1.63 ± 0.45 1.62 ± 0.51 0.924
C18-dihydro-ceramide 37.27 ± 4.89 41.96 ± 7.72 0.009* 41.98 ± 6.75 41.90 ± 9.34 0.961
C18:1-ceramide 0.43 ± 0.02 0.45 ± 0.07 0.153 0.45 ± 0.03 0.45 ± 0.11 0.925
C20-ceramide 0.96 ± 0.44 1.23 ± 0.86 0.089 1.20 ± 0.56 1.29 ± 1.26 0.634
C22-ceramide 9.15 ± 3.50 12.62 ± 9.39 0.109 12.30 ± 4.90 13.27 ± 14.79 0.635
C24:1-ceramide 3.92 ± 1.54 6.20 ± 4.81 0.040* 5.87 ± 2.87 6.99 ± 7.27 0.263
  1. *P< 0.05